Biotechnology company Moderna announced Monday that preliminary data suggests its half-dose booster shot increased antibody levels against Omicron compared with the levels seen when a fully vaccinated person does not receive a booster — and a larger-sized dose of the booster increases antibody levels even more.
Currently, Moderna’s booster is administered as a 50-microgram dose. The company announcement noted that its 50-microgram booster dose increased antibody levels 37-fold and a 100-microgram booster dose increased antibody levels 83-fold compared with levels seen before a booster. It remains unclear what these increases mean as far as how well the booster doses clinically work against Omicron.
But in the company’s statement, CEO Stéphane Bancel called the data “reassuring.” “The dramatic increase in COVID-19 cases from the Omicron variant is concerning to all. However, these data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37-fold higher than pre-boost levels are reassuring,” Bancel said in the announcement.
“To respond to this highly transmissible variant, Moderna will continue to rapidly advance an Omicron-specific booster candidate into clinical testing in case it becomes necessary in the future. We will also continue to generate and share data across our booster strategies with public health authorities to help them make evidence-based decisions on the best vaccination strategies against SARS-CoV-2.” SARS-CoV-2 is the name of the coronavirus that causes Covid-19.